Norway-based NattoPharma ASA held Board of Directors elections at its Annual General Meeting on May 20, and Frode Marc Bohan was re-elected as chairman of the board of directors for a period of two years. The company also increased the board of directors from three to five members, with the addition of Stefan Halldén and Annette Emlqvist, who were elected for a two-year period each, until the ordinary Annual General Meeting in 2018.
 
Stefan Halldén is a working chairman of Life Science Sweden AB, a long time shareholder in NattoPharma and a valuable contributor to the development of the company. In the last year he also held the position as a member of the election committee. Mr. Halldén has a long track record in international finance.
 
Anette Elmqvist has an extensive operational experience from various health and pharma companies as Swedish Pharmacies, KabiVitrum AB, Pharmacia Biopharmaceuticals AB, Pharmacia & Upjohn AB, Active Biotech AB, PowderJect SBL Vaccin AB, SBL Vaccin AB, and Unitech Biopharma AB. Today, Ms. Elmqvist serves as vice president of quality assurance for Scandinavian Biopharma AB.
 
“The election of Stefan Halldén and Annette Elmqvist as members of the board of directors in NattoPharma ASA is continuing the efforts to move NattoPharma from an ‘entrepreneurial start up company’ within the dietary supplement business segment to a visible player within global biotechnology, nutraceutical, and pharmaceutical fields,” said Frode M. Bohan, chairman of the board in NattoPharma. “Annette Elmqvist extensive operational and pharmaceutical production experience will be a great asset for NattoPharma. Combined with Stefan Halldén extensive financial background, I believe that the extended board will contribute greatly to the success of NattoPharma ASA.”